Aspire Biopharma Holdings, Inc.
ASBP
$0.11
$0.0113.05%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 109.96% | -61.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.44% | -43.87% | |||
| Operating Income | -43.21% | 43.87% | |||
| Income Before Tax | 6.60% | 87.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.60% | 87.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.60% | 87.57% | |||
| EBIT | -43.21% | 43.87% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 6.97% | 90.44% | |||
| Normalized Basic EPS | -14.15% | 31.44% | |||
| EPS Diluted | 6.97% | 90.44% | |||
| Normalized Diluted EPS | -14.15% | 31.44% | |||
| Average Basic Shares Outstanding | 0.39% | 30.20% | |||
| Average Diluted Shares Outstanding | 0.39% | 30.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||